Dataset Information

Integrated Cancer Repository for Cancer Research

ABSTRACT: The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

DISEASE(S): Endometrial Cancer,Plasma Cell Dyscrasia,Thyroid Neoplasms,Lynch Syndrome,Mesothelioma,Thymus Neoplasms,Endometrial Neoplasms,Laryngeal Cancer,Neoplasms,Duodenal Cancer,Esophageal Neoplasms,Cns Cancer,Colon Cancer,Bile Duct Cancer,Familial Adenomatous Polyposis,Nasal Cavity Cancer,Nasopharyngeal Neoplasms,Lip Neoplasms,Multiple Myeloma,Salivary Gland Neoplasms,Thymus Cancer,Peritoneal Surface Malignancies,Nasopharyngeal Carcinoma,Vaginal Cancer,Laryngeal Neoplasms,Vaginal Neoplasms,Melanoma,Adenomatous Polyposis Coli,Oral Cavity Cancer,Pancreatic Cancer,Colorectal Neoplasms, Hereditary Nonpolyposis,Penile Neoplasms,Esophageal Cancer,Anal Cancer,Kidney Cancer,Oropharyngeal Neoplasms,Intestinal Neoplasms,Neoplasms, Plasma Cell,Testicular Neoplasms,Urethral Cancer,Neuroendocrine Tumors,Gist,Lung Cancer,Salivary Gland Cancer,Leukemia,Liver Cancer,Testicular Cancer,Nasopharyngeal Cancer,Ureter Cancer,Paranasal Sinus Cancer,Ovarian Cancer,Skin Cancer,Ureteral Neoplasms,Paranasal Sinus Neoplasms,Gastric Cancer,Paraproteinemias,Unknown Primary Tumor,Pancreatic Neoplasms,Penile Cancer,Sarcoma,Lip Cancer,Neoplasms, Unknown Primary,Duodenal Neoplasms,Bladder Cancer,Small Intestine Cancer,Hypopharyngeal Neoplasms,Rectal Cancer,Gallbladder Cancer,Breast Cancer,Oropharyngeal Cancer,Anus Neoplasms,Mouth Neoplasms,Urethral Neoplasms,Peritoneal Neoplasms,Hypopharyngeal Cancer,Thyroid Cancer,Gallbladder Neoplasms,Bile Duct Neoplasms,Prostate Cancer,Cns Tumor

PROVIDER: 2156977 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Next Generation Sequencing (NGS) technologies are being used for detection of somatic mutations in tumors and studies of germline variation. However, most NGS studies used DNA isolated either from whole blood or fresh frozen tissue specimens. Meanwhile, the tissue specimens available from most National Cancer Institute (NCI) funded cohorts and the Surveillance, Epidemiology and End Results (SEER) registries (<a href="http://seer.cancer.gov/biospecimen">http://seer.cancer.gov/biospecimen</a>) are primarily formalin fixed paraffin embedded (FFPE). There are limited data, on a small number of FFPE tissue samples, which suggest NGS is feasible. Much less is known about the feasibility of these technologies for large scale studies or using older FFPE specimens (e.g. 5-30 years old). The SEER cancer registries cover approximately 28% of the United States population, providing high quality demographic, clinical, pathologic, and survival data. The SEER Residual Tissue Repository (RTR) program was established in 2003. The RTR maintains biospecimens obtained from three of SEER' population-based cancer registries: Iowa, Hawaii, and Los Angeles. Investigators at government, academic, and nonprofit institutions may apply to the program to obtain annotated FFPE tumor tissue specimens to study biomarkers, etiology, and other aspects with a population-based sample of cancer cases. The main objective of this project was to conduct a pilot study to determine whether the DNA obtained from archival FFPE tissue from 3 SEER Registries is of sufficient quality and quantity to conduct NGS. For Exome sequencing, sixty high-grade serous ovarian adenocarcinomas from FFPE tissues which were between 7 and 31 years old were obtained from three SEER registries. DNA was extracted, quantified, quality assessed, and subjected to whole exome sequencing. DNA extraction (yields and quality) and whole exome sequencing (depths of coverage and exome coverage obtained) results from this study will be presented. For RNA-sequencing, sixty-seven high-grade serous ovarian adenocarcinomas from FFPE tissues which were between 7 and 31 years old were obtained from three SEER registries. Total RNA was extracted, quantified, quality assessed, and subjected to whole transcriptome sequencing. Ultimately data derived from this analysis could serve as the basis for determining the utility of archival FFPE biospecimens for characterization and discovery projects utilizing NGS technologies instead of relying on frozen biospecimens.

Dataset Information

Integrated Cancer Repository for Cancer Research

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets